New Horizons on Molecular Pharmacology Applied to Drug Discovery: When Resonance Overcomes Radioligand Binding

Autor(es)

Pernomian, Larissa ; Gomes, Mayara Santos ; Moreira, Josimar Dornelas ; Tomich de Paula da Silva, Carlos Henrique ; Campos Rosa, Joaquin Maria ; de Barros Cardoso, Cristina Ribeiro

• Tipo de documento: Artigo de Revisão
• Fonte: CURRENT RADIOPHARMACEUTICALS; v. 10, n. 1, p. 16-20, 2017.
• Citações Web of Science: 0

Resumo

One of the cornerstones of rational drug development is the measurement of molecular parameters derived from ligand-receptor interaction, which guides therapeutic windows definition. Over the last decades, radioligand binding has provided valuable contributions in this field as key method for such purposes. However, its limitations spurred the development of more exquisite techniques for determining such parameters. For instance, safety risks related to radioactivity waste, expensive and controlled disposal of radioisotopes, radiotracer separation-dependence for affinity analysis, and one-site mathematical models-based fitting of data make radioligand binding a suboptimal approach in providing measures of actual affinity conformations from ligands and G protein-coupled receptors (GPCR). Current advances on high-throughput screening (HTS) assays have markedly extended the options of sparing sensitive ways for monitoring ligand affinity. The advent of the novel bioluminescent donor NanoLuc luciferase (Nluc), engineered from Oplophorus gracilirostris luciferase, allowed fitting bioluminescence resonance energy transfer (BRET) for monitoring ligand binding. Such novel approach named Nluc-based BRET (NanoBRET) binding assay consists of a real-time homogeneous proximity assay that overcomes radioligand binding limitations but ensures the quality in affinity measurements. Here, we cover the main advantages of NanoBRET protocol and the undesirable drawbacks of radioligand binding as molecular methods that span pharmacological toolbox applied to Drug Discovery. Also, we provide a novel perspective for the application of NanoBRET technology in affinity assays for multiple-state binding mechanisms involving oligomerization and/or functional biased selectivity. This new angle was proposed based on specific biophysical criteria required for the real-time homogeneity assigned to the proximity NanoBRET protocol. (AU)

• Processo FAPESP: 12/00640-7 - Estudo das consequências do processo inflamatório induzido por receptores AT1 durante aterosclerose sobre o eixo ECA2 - angiotensina-(1-7) -Mas em aorta de camundongo e da participação de receptores Mas nos efeitos vaso- e ateroprotetores de losartan
• Beneficiário: Larissa Pernomian
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 14/17740-0 - Planejamento, desenvolvimento e avaliação farmacológica de novos antagonistas de receptores para hidrocarbonetos arila (AhR) candidatos a fármacos ateroprotetores
• Beneficiário: Larissa Pernomian
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 12/09019-3 - Consequências da dislipidemia sobre os eixos ECA - Ang II - AT1 e ECA2 - Ang-(1-7) - mas do sistema angiotensinérgico em aorta de camundongos LDLr knockout jovens e adultos
• Beneficiário: Ana Maria de Oliveira
• Modalidade de apoio: Auxílio à Pesquisa - Regular